Investing.com - 10X Genomics (NASDAQ: TXG) reported fourth quarter EPS of $-0.13, $0.09 better than the analyst estimate of $-0.22. Revenue for the quarter came in at $166M versus the consensus estimate of $157.73M.
10X Genomics sees FY 2026 revenue of $600.00M-$625.00M versus the analyst consensus of $611.80M.
10X Genomics’s stock price closed at $17.51. It is up 10.20% in the last 3 months and up 46.65% in the last 12 months.
10X Genomics saw 3 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See 10X Genomics’s stock price’s past reactions to earnings here.
According to InvestingPro, 10X Genomics’s Financial Health score is "good performance".
Check out 10X Genomics’s recent earnings performance, and 10X Genomics’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar
Most traders can read a chart. The hard part is the moment: entry window open, pattern forming, and you're still waiting for more confirmation. That's the conviction gap — and our chart analysis closes it. Unlike other AIs that just read data, our Vision AI literally "sees" your charts and hands you a complete trading plan: entry, stop-loss, and profit target in under 60 seconds. Know exactly what to do next, every time.